- Home
- MMU vs RIGL Comparison
MMU vs RIGL Comparison
Compare MMU & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMU
- RIGL
- Stock Information
- Founded
- MMU 1992
- RIGL 1996
- Country
- MMU United States
- RIGL United States
- Employees
- MMU N/A
- RIGL N/A
- Industry
- MMU Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- MMU Finance
- RIGL Health Care
- Exchange
- MMU Nasdaq
- RIGL Nasdaq
- Market Cap
- MMU 572.4M
- RIGL 366.5M
- IPO Year
- MMU N/A
- RIGL 2000
- Fundamental
- Price
- MMU $10.16
- RIGL $19.91
- Analyst Decision
- MMU
- RIGL Buy
- Analyst Count
- MMU 0
- RIGL 5
- Target Price
- MMU N/A
- RIGL $36.80
- AVG Volume (30 Days)
- MMU 170.7K
- RIGL 219.4K
- Earning Date
- MMU 01-01-0001
- RIGL 03-04-2025
- Dividend Yield
- MMU 4.92%
- RIGL N/A
- EPS Growth
- MMU N/A
- RIGL N/A
- EPS
- MMU N/A
- RIGL 0.99
- Revenue
- MMU N/A
- RIGL $179,278,000.00
- Revenue This Year
- MMU N/A
- RIGL $14.19
- Revenue Next Year
- MMU N/A
- RIGL $13.10
- P/E Ratio
- MMU N/A
- RIGL $20.64
- Revenue Growth
- MMU N/A
- RIGL 54.71
- 52 Week Low
- MMU $8.60
- RIGL $7.48
- 52 Week High
- MMU $10.45
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- MMU 31.56
- RIGL 45.28
- Support Level
- MMU $10.40
- RIGL $18.44
- Resistance Level
- MMU $10.53
- RIGL $20.88
- Average True Range (ATR)
- MMU 0.09
- RIGL 1.55
- MACD
- MMU -0.03
- RIGL -0.24
- Stochastic Oscillator
- MMU 2.63
- RIGL 29.05
About MMU Western Asset Managed Municipals Fund Inc.
Western Asset Managed Municipals Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is to maximize current income exempted from federal income tax as is consistent with the preservation of principal. It predominantly invests in long-term investment grade municipal debt securities issued by state and local governments, political subdivisions, agencies, and public authorities (municipal obligations). Under normal market conditions, a majority of its total assets are invested in municipal obligations rated investment grade at the time of investment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.